AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Sanofi, RadioMedix, and Orano Med Partner on Next-Generation Radioligand Therapy for Rare Cancers

NextEdge Admin

13 Sep 2024

2 min 2 sec

RadioMedix,Orano Med,radioligand medicine

Sanofi has entered an exclusive licensing agreement with RadioMedix, Inc., a U.S. clinical-stage biotech firm specializing in radiopharmaceuticals, and Orano Med, a French subsidiary of Orano Group focused on radioligand therapies (RLTs) for cancer treatment. The collaboration centers on AlphaMedix™ (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) being evaluated for treating patients with metastatic, progressive neuroendocrine tumors (NETs) that express somatostatin receptors.

AlphaMedix™ is a peptide complex radiolabeled with lead-212 (212Pb), an alpha particle generator. Early clinical results showed a 62.5% durable response rate in reducing tumor burden, leading to its Breakthrough Therapy Designation by the U.S. FDA for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Sanofi's Chief Medical Officer, Dietmar Berger, highlighted the potential of 212Pb as a transformative therapy for rare cancers, while Ebrahim S. Delpassand, CEO of RadioMedix, emphasized its role in pioneering nuclear oncology. Orano Med CEO Julien Dodet affirmed their commitment to advancing 212Pb-based therapies, developing a global platform for AlphaMedix™ manufacturing and distribution.

Sanofi will oversee global commercialization, while Orano Med handles manufacturing. The deal includes an upfront payment of €100 million, up to €220 million in sales milestones, and tiered royalties, pending regulatory approval. This agreement aligns with Sanofi's strategic focus on innovation in oncology, addressing hard-to-treat cancers through targeted therapies.